Origin Pharma Packaging Expand Cleanroom Manufacturing to Meet Demand
As legislation and ethical awareness evolves, Origin Pharma Packaging has seen the demand for innovative design and production of child-safe packaging increase on a global scale.
Our new product development (NPD) team are continually investing their time and knowledge in developing commercial solutions for child-resistant compliant packaging for the UK, Europe, the US and beyond.
During the past twenty-four months, Origin Pharma Packaging has partnered custom design and manufacturing projects not compatible with the larger manufacturing sites across the Hybrid Pharma Packaging (HP3) network. As a result, Origin has added a new cleanroom manufacturing facility to the HP3 network, located in Melton, East Yorkshire, UK.
Origin has executed a multi-million-pound investment programme at its Centre of Excellence for Pharmaceutical Packaging Design & Innovation. Installing and delivering a cleanroom production facility to ISO 7 (class 10,000) or ISO8 (class 100,000) boosting the capabilities of the existing HP3 network. The facility is equipped for the manufacture of injection moulded (IM), injection stretch blow moulded (ISBM) and injection blow moulded (IBM) parts.
Cleanroom production facility key facts:
- Classification: ISO7/ class 10,000 to ISO8/ class 100,000
- Compliant with ISO14644 and ISO9001-ISO 15378
- Processes (all-electric): IM), ISBM and IBM
- Automatic assembly
The HP3 network required the addition of this specific facility at a regional level, combining cleanroom classification, multiple ISO and good manufacturing practice (GMP) compliance, Medicines and Healthcare Products Regulatory Agency (MHRA) pursuit, European Pharmacopoeia (EUPh) compliant raw material sources, custom flexibility and integral supply chain assurance.
Due to the urgency of a sponsor project, a global pharmaceuticals manufacturing company, Origin executed and delivered the cleanroom production facility within four months. It is now fully functional, and production commenced in Q1 2018.